Pemvidutide (ALT-801): IMPACT Phase 2b 48-Week MASH
Altimmune's Pemvidutide (ALT-801): GLP-1/glucagon dual agonist. IMPACT Phase 2b 48-week ELF -0.58, LSM -3.97, liver fat -54.7%. FDA Breakthrough.
Introduction: The Next Incretin After Semaglutide and Tirzepatide
After GLP-1 monotherapy (Semaglutide ESSENCE[1]) and GLP-1/GIP dual (Tirzepatide SYNERGY-NASH) demonstrated positive MASH fibrosis endpoints in 2024–2025, the competitive axis in incretin-based MASH drugs has shifted to which receptor combination to target. Adding glucagon receptor agonism brings direct hepatic effects (β-oxidation enhancement, suppression of de novo lipogenesis), making it an attractive add-on to GLP-1 mechanism.
The leading GLP-1/glucagon dual candidate is Pemvidutide (development code ALT-801), developed by Altimmune (Gaithersburg, MD). The IMPACT Phase 2b trial (NCT05989711, n=212) 48-week topline was announced December 19, 2025, demonstrating statistically significant improvements in non-invasive fibrosis markers (ELF, LSM) versus placebo, leading to FDA Breakthrough Therapy Designation on January 5, 2026[2][3]. This article reviews the compound profile, IMPACT clinical data, head-to-head considerations against Semaglutide / Tirzepatide / Survodutide / Resmetirom, and Phase 3 strategy based exclusively on public sources.
1. Compound Profile
| Attribute | Detail |
|---|---|
| INN / generic name | Pemvidutide |
| Development codes | ALT-801 (formerly SP-1373, VPD-1070) |
| Sponsor | Altimmune, Inc. (Gaithersburg, Maryland) |
| Origination & licensing | Altimmune in-house discovery (formerly Vaxin Inc → renamed Altimmune in 2015 → merged with PharmAthene in 2017). No external licensing chain |
| Modality | Peptide-based GLP-1 / glucagon dual receptor agonist (1:1 balanced), subcutaneous (SC), once-weekly |
| Indications | MASH (lead), obesity / overweight, alcohol use disorder (AUD), alcohol-associated liver disease (ALD) |
| Regulatory designations | FDA Breakthrough Therapy Designation (Jan 5, 2026, MASH), FDA Fast Track (MASH and AUD) |
| Status | IMPACT Phase 2b (NCT05989711) 48-week topline complete (Dec 19, 2025), Phase 3 initiation planned in 2026 (52-week biopsy endpoint) |
Pemvidutide is a single peptide with 1:1 balanced potency at GLP-1 and glucagon receptors, distinguishing it from Tirzepatide (GLP-1/GIP) and from Survodutide (Boehringer's GLP-1/glucagon dual with different glucagon-receptor potency ratio).
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
2. Therapeutic Hypothesis: GLP-1/Glucagon Dual Agonism
GLP-1 monotherapy treats MASH primarily through an indirect path: appetite suppression → weight loss → reduced hepatic fat → fibrosis benefit. GLP-1/glucagon duals like Pemvidutide add direct hepatic effects through glucagon receptor activation:
- Enhanced hepatic β-oxidation: increased mitochondrial fatty-acid oxidation in hepatocytes
- Suppression of de novo lipogenesis: blocks SREBP-1c-driven lipogenic gene expression
- Increased energy expenditure (thermogenesis): UCP1-mediated systemic basal metabolic rate elevation
This "appetite suppression + direct hepatic action + systemic metabolic activation" trifecta is hypothesized to outperform GLP-1 monotherapy on weight loss and hepatic fat. IMPACT confirmed this directionally — hepatic fat content reduction reached -54.7% at 24 weeks (vs -8.2% placebo), exceeding Semaglutide's comparable-window MASH data[2].
3. IMPACT Phase 2b Trial Design
| Parameter | Detail |
|---|---|
| Trial number | NCT05989711 |
| Design | Phase 2b, randomized, placebo-controlled, double-blind, multicenter, international |
| Patients | Biopsy-confirmed MASH, F2 or F3 fibrosis, with or without diabetes |
| Sample size | n=212 |
| Randomization | 1:2:2 (1.2 mg : 1.8 mg : placebo) = 38:76:76 |
| Dose / route | 1.2 mg or 1.8 mg, weekly SC, 48 weeks |
| Primary endpoints | Histologic MASH resolution (without fibrosis worsening) and ≥1-stage fibrosis improvement (without MASH worsening) at week 48; week-24 MRI-PDFF; week-48 ELF and LSM |
| Secondary endpoints | Weight change, HbA1c, lipid profile, safety |
4. IMPACT 48-Week Topline (Announced Dec 19, 2025)
4.1 Non-Invasive Fibrosis Markers (ELF, LSM at 48 weeks)[2]
| Parameter | Placebo | Pemvidutide 1.2 mg | Pemvidutide 1.8 mg |
|---|---|---|---|
| ELF score mean change | +0.16 | -0.49 (p<0.0001) | -0.58 (p<0.0001) |
| LSM (FibroScan kPa) mean change | -0.03 | -3.04 (p<0.05) | -3.97 (p<0.001) |
| Composite responders (ELF≥0.5 reduction + LSM ≥30% reduction) | 3.2% | 27.8% (p<0.001) | 32.4% (p<0.0001) |
Interpretation: ELF reductions ≥0.5 and LSM reductions ≥30% are widely accepted as clinically meaningful treatment-response thresholds. Pemvidutide produced composite responder rates 9–10× over placebo (27.8–32.4% vs 3.2%), a strong fibrosis-related non-invasive outcome signal.
4.2 Hepatic Fat Content (MRI-PDFF, 24 weeks)
- 1.2 mg: -45.2%, 1.8 mg: -54.7%, placebo: -8.2% (p<0.0001, both doses)
- The proportion of patients with ≥30% hepatic fat reduction (including FAST score ≤0.35 achievement) exceeded 50% in both treatment arms
4.3 Weight and Metabolic Outcomes (24 weeks)
| Parameter | Placebo | Pemvidutide 1.2 mg | Pemvidutide 1.8 mg |
|---|---|---|---|
| Weight loss | -1.0% | -5.0% (p<0.001) | -6.2% (p<0.001) |
4.4 Safety / Tolerability
- AE-related discontinuation: 1.2 mg 0.0% / 1.8 mg 1.2% / placebo 2.4% (lower than placebo)
- No drug-related serious AEs reported
- Major AEs were the typical GLP-1-class GI events (nausea, vomiting, diarrhea), generally mild to moderate
Note: As of April 2026, IMPACT Phase 2b data have been disclosed via AASLD The Liver Meeting 2025 oral late-breaking presentation + late-breaking poster[4]; a peer-reviewed full publication (NEJM, Lancet, JHEP) is not yet available. Detailed numbers for histologic MASH resolution and fibrosis improvement remain at AASLD 2025 abstract level.
5. Class Comparison: Pemvidutide vs Semaglutide / Tirzepatide / Survodutide / Resmetirom
| Axis | Pemvidutide | Semaglutide ESSENCE[1] | Tirzepatide SYNERGY-NASH | Survodutide | Resmetirom MAESTRO-NASH[5] |
|---|---|---|---|---|---|
| Target | GLP-1/glucagon dual | GLP-1 | GLP-1/GIP dual | GLP-1/glucagon dual | THR-β |
| Route | Weekly SC | Weekly SC | Weekly SC | Weekly SC | Once-daily oral |
| Trial | IMPACT Phase 2b 48-week | ESSENCE Phase 3 (Part 1, 72-week) | SYNERGY-NASH Phase 2 52-week | Phase 2 48-week | MAESTRO-NASH Phase 3 52-week |
| Sample size | 212 | 800 | 190 | 295 | 966 |
| MASH resolution (high dose) | AASLD 2025 abstract (numbers not disclosed) | 62.9% vs 34.1% | 51.8% vs 9.8% | 83% (highest dose) vs 18% | 30% vs 10% |
| Fibrosis improvement (high dose) | ELF/LSM significant | 36.8% vs 22.4% | 50% vs 15% | 64.5% vs 25.9% | 26% vs 14% |
| Hepatic fat reduction (MRI-PDFF) | -54.7% (24-week) | ~-50% est. | -65% | -64.5% | -37% |
| Weight loss (high dose) | -6.2% (24-week) | -10.5% (72-week) | -22% | -19% | ±0% |
| Approval status | Phase 2b → Phase 3 in planning | 2025 ESSENCE Part 1 publication, Phase 3 continues | Phase 3 in planning | Phase 3 ongoing | March 2024 FDA accelerated approval |
Key points:
- Pemvidutide's weight loss (-6.2%) is moderate among dual/triple class (Survodutide -19%, Tirzepatide -22% are stronger). This likely reflects Pemvidutide's relatively lower glucagon receptor potency setting.
- Hepatic fat reduction (-54.7%) approaches Tirzepatide (-65%), indicating direct hepatic effects from dual agonism.
- Non-invasive fibrosis marker (ELF, LSM) improvements rank among the strongest in the dual class. If histologic MASH resolution / fibrosis improvement numbers in Phase 3 confirm this, Pemvidutide becomes the leading SC alternative to Resmetirom.
- Survodutide is primarily an obesity asset — its MASH Phase 3 design is undefined. Pemvidutide's strategic differentiator is MASH-as-lead-indication for registration trials.
6. Phase 3 Strategy
6.1 Phase 3 Trial Design
Following the End-of-Phase 2 meeting with FDA in 2025, Altimmune disclosed the Phase 3 registration trial design parameters[3]:
- 52-week biopsy endpoint (MASH resolution and/or ≥1-stage fibrosis improvement, each without worsening of the other)
- Multiple doses (likely including both 1.2 mg and 1.8 mg)
- AIM-MASH AI Assist: AI-supported biopsy histology adjudication for improved precision
- EMA scientific advice in parallel: setting up for European Phase 3 simultaneously
6.2 Timeline
- Phase 3 initiation in 2026 (publicly committed)
- 52-week trial + data lock + filing standard pipeline → realistic FDA accelerated approval ~2029–2030
- Conventional approval (Phase 4 long-term outcomes) is realistic 2032 or later
6.3 Indication Expansion
Pemvidutide is being developed under a multi-indication strategy:
- MASH (lead, IMPACT Phase 2b complete)
- Obesity / overweight (Phase 2 complete; competing with Tirzepatide / Semaglutide)
- Alcohol use disorder (AUD): RECLAIM Phase 2 enrollment completed early (2025)
- Alcohol-associated liver disease (ALD): exploratory phase
Whether to compete head-on with Tirzepatide / Semaglutide as an obesity asset, or to differentiate as a MASH-specialized SC dual agent, is the inflection point in Altimmune's strategy.
7. Competitive Pipeline Overview
The MASH drug landscape is consolidating into three groups:
- THR-β (oral): Resmetirom (approved), VK2809 (Phase 2b complete)
- FGF21 analogs (SC): Efruxifermin (Akero/Novo), Pegozafermin (89bio/Roche)
- GLP-1 family (SC, weekly): Semaglutide ESSENCE, Tirzepatide SYNERGY-NASH, Survodutide, Pemvidutide (this article)
- Other (oral): Lanifibranor panPPAR, Denifanstat FASN
Pemvidutide's strategic positioning: superior hepatic effects vs GLP-1 monotherapy, but not as strong on weight loss as Tirzepatide. By focusing on MASH-specialized dual clarity, it targets the niche of "Resmetirom oral alternative + Semaglutide SC enhancement." See MASH Drug Landscape 2025 and GLP-1 Antifibrotic Outlook.
8. FAQ
Q1. How is Pemvidutide different from Survodutide? Aren't both GLP-1/glucagon duals?
A. Both are GLP-1/glucagon duals but differ in glucagon-receptor potency ratio. Survodutide (Boehringer BI 456906) is glucagon-heavy with -19% weight loss and very strong metabolic activation; Pemvidutide is 1:1 balanced, designed to balance hepatic effect and weight loss. Survodutide has obesity as primary indication and runs Phase 3 there; Pemvidutide leads with MASH for registration trials — strategically distinct programs.
Q2. What about histologic MASH resolution and fibrosis improvement at 48 weeks in IMPACT?
A. As of April 2026, the data were disclosed at AASLD 2025 (Nov 2025) late-breaking session, but specific histologic numbers are not publicly disclosed at the press-release level[4]. Detailed numbers will be confirmed when the peer-reviewed publication (NEJM, JHEP, or Lancet) appears. Currently disclosed outcomes are limited to ELF, LSM, and MRI-PDFF.
Q3. Are ELF score changes of -0.49 to -0.58 clinically meaningful?
A. ELF score reductions ≥0.5 are widely accepted as treatment-response thresholds. ELF (a 3-component panel of PRO-C3, TIMP-1, hyaluronic acid) reflects dynamic ECM turnover. A placebo +0.16 vs Pemvidutide -0.58 differential at 48 weeks corresponds to a ~0.74-point separation, which is clinically and statistically meaningful for MASH treatment response. See ELF score for details.
Q4. Why use AIM-MASH AI Assist in Phase 3?
A. Central biopsy adjudication faces structural reader-to-reader variability (kappa ~0.5–0.7), which dilutes detectable treatment effect in Phase 3. AIM-MASH (PathAI-developed) supports NAS scoring and fibrosis staging via AI, reducing reader variability and improving statistical power. Since 2024, FDA has signaled willingness to accept AI-assist pathology in MASH Phase 3 trials[3].
Q5. Could Pemvidutide become an oral drug?
A. Pemvidutide is currently a peptide-only SC weekly injection. Oral GLP-1 (Rybelsus) demonstrates that absorption-enhancing formulation is technically possible, but Altimmune has not announced an oral development plan. Resmetirom currently dominates the oral MASH category, so Pemvidutide appears positioned to compete in the SC niche.
9. Conclusion: The Leading Candidate to Prove "Dual Wins"
Pemvidutide presents:
- GLP-1/glucagon 1:1 balanced dual with clear mechanistic differentiation
- IMPACT Phase 2b 48-week ELF -0.58, LSM -3.97 kPa, hepatic fat -54.7% — robust non-invasive outcomes
- FDA Breakthrough Therapy Designation (MASH, Jan 2026) + Fast Track (MASH/AUD) regulatory package
- Phase 3 initiation in 2026 with 52-week biopsy endpoint and AIM-MASH AI Assist
- Multi-indication strategy: MASH / obesity / AUD / ALD across four indications
The 2027–2029 critical question for MASH will be: how much hepatic-selective efficacy can Pemvidutide demonstrate in Phase 3, post-Resmetirom oral approval? From a fibrosis biomarker perspective, the extent to which FIB-4, ELF, PRO-C3, and LSM are integrated into Phase 3 design will materially impact regulatory speed and Phase 4 long-term outcomes trial design.
References
[1] Sanyal AJ, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089-2099. PMID: 40305708 (ESSENCE Part 1)
[2] Altimmune, Inc., Press Release. "Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial" (Dec 19, 2025). Detail: ELF -0.49 (1.2 mg) / -0.58 (1.8 mg) vs +0.16 placebo (p<0.0001); LSM -3.04 (p<0.05) / -3.97 (p<0.001) vs -0.03; hepatic fat -45.2 / -54.7% vs -8.2% (p<0.0001).
[3] Altimmune, Inc., Press Releases. "Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH" (Jan 5, 2026) and "Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide" (2025).
[4] Altimmune, Inc., Press Release. "Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025" (Oct 22, 2025).
[5] Harrison SA, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497-509. PMID: 38324483
Related Articles
- Semaglutide ESSENCE Phase 3
- Survodutide (GLP-1/GCG Dual): BI 456906
- GLP-1 Antifibrotic Outlook: Beyond Semaglutide
- VK2809 (Viking THR-β): VOYAGE Phase 2b
- Resmetirom (Rezdiffra): First MASH Approval
- Efruxifermin (FGF21): HARMONY/SYMMETRY
- Pegozafermin (FGF21 Analog)
- Lanifibranor (panPPAR): NATiV3
- Denifanstat (FASN): FASCINATE-2
- MASH Drug Landscape 2025
- MASH Drug Future Landscape
- ELF Score Complete Guide
- FIB-4 Score Complete Guide
- PRO-C3: MASH Treatment Response Marker